Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: A single-arm, phase II trial
Short-and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial
Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck
P3. 02b-117 Phase Ib Results from a Study of Capmatinib (INC280)+ EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR RES
Neoadjuvant cytoreductive treatment of regionally advanced melanoma with braf/mek inhibition: study protocol of the REDUCTOR (cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patients with braf mutated, prior unresectable stage iii or iv melanoma) trial